Child and Adolescent Psychopharmacology News

Edited by Adelaide S. Robb, MD
Children’s National Health System; George Washington University

ISSN: 10850295

As of December 2018, Child and Adolescent Psychopharmacology News will cease publication with Volume 22, Number 6. Please contact news@guilford.com for any further information.

With psychotropic medications now widely used in the treatment of children and adolescents, you need a way to keep up to date and fully informed about current best practices in the field. From respected experts, Child & Adolescent Psychopharmacology News offers you:

"Child and Adolescent Psychopharmacology News provides the mental health clinician, whether medical or nonmedical, with state-of-the-art information on the medical treatments available for psychiatric disorders in children and teens. Contributors are internationally recognized experts who are able to communicate complicated ideas in language that is comprehensible to medical and nonmedical professionals alike. A 'must' for psychologists, social workers, or pediatricians who work collaboratively with child psychiatrists."

-Gwenyth Edwards, PhD


"As a developmental pediatrician who prescribes a significant amount of medication for a variety of developmental disorders, I find CAPN extremely useful for keeping up to date with the literature on medication studies. I can learn of new applications and preparations as well as possible side effects and drug interactions in a timely way and in a format that allows fast and efficient reading. I think that all pediatricians will find this a very valuable source of information."

-Wendy Roberts, MD, FRCP(C), The Hospital for Sick Children, Toronto, Ontario, Canada


"A valuable source for practitioners who need succinct and accurate updates regarding innovative and state-of-the-art psychopharmacological treatments for children and adolescents."

-Ronald T. Brown, PhD

Editorial Board

Associate Editor:
Molly K. McVoy, MD
Case Western Reserve University

Research Editor:
Erin Fulchiero, MD and Samantha Imfeld, MD
University Hospitals Cleveland Medical Center

Editorial Board:
Gabrielle Carlson, Normand Carrey, Laurence Greenhill, Bruce Meltzer, Lukas Propper, Dara J. Sakolsky, Robert Stansbrey

Regular Features

Child & Adolescent Psychopharmacology News will keep you informed about important research, issues, controversies, and events that have an impact on your field. The newsletter regularly includes these features:

REVIEW OF MEDICATIONS
Learn how new medications affect child populations by reading about their pharmacokinetics and mechanisms of action

HOW-TO SECTIONS
Read about the use of specific drugs in specific situations, including ways to:
NEW RESEARCH
Stay on top of what's being published around the world with synopses and critical commentary

OPINION PIECES
Read what well-respected clinicians and researchers have to say on timely and relevant topics

TREATMENT ISSUES
Find out what the research says about the pharmacologic treatment of specific psychiatric disorders in children and adolescents

PRACTITIONER POINTERS
Get inside information on the methods and techniques clinicians are talking about with each other

USEFUL INSERTS
Keep helpful information at your fingertips or use as handouts for clients

About the Editor

Adelaide S. Robb, MD, is a psychopharmacologist with ongoing research studies in major depression, anxiety, bipolar disorder, schizophrenia, autism, and ADHD for medication management. Dr. Robb is Chief of the Division of Psychology and Behavioral Health, at Children’s National Health System, which aims to combine psychological and psychiatric services to treat the medically ill child, and is a Professor of Psychiatry and Pediatrics at the George Washington University.

Dr. Robb, who trained at Johns Hopkins University and the National Institutes of Health, has been on the medical staff in the Division of Psychiatry and Behavioral Medicine since 1996, rising to the rank of Professor (with tenure). She is an internationally known clinical researcher and directs a large clinical trial program in pediatric psychopharmacology for new agents being tested for FDA approval in children and teens.